Mint Pharmaceuticals Inc Pharmaceutical Import Profile — Canada (DGFT 2022–2026)

Name: Mint Pharmaceuticals Inc Pharmaceutical Import Records from India — 4 Products, $2.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Mint Pharmaceuticals Inc — Pharmaceutical Importer Profile (2026) | 4 Products, $2.5M Trade | TransData Nexus

Mint Pharmaceuticals Inc

Pharmaceutical Importer · Canada · Diuretics Focus · $2.5M Total Trade · DGFT Verified

Mint Pharmaceuticals Inc is a pharmaceutical importer based in Canada with a total trade value of $2.5M across 4 products in 3 therapeutic categories. Based on 53 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Mint Pharmaceuticals Inc sources from 20 verified Indian suppliers, with Cohance Lifesciences Limited accounting for 14.4% of imports.

Mint Pharmaceuticals Inc — Import Portfolio & Supplier Network

Mint Pharmaceuticals Inc import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Mint Pharmaceuticals Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cohance Lifesciences Limited	$1.7M	54	14.4%
Zenara Pharma Private Limited	$1.6M	61	12.9%
Hetero Labs Limited	$1.5M

What Formulations Does Mint Pharmaceuticals Inc Import?

Formulation	Value	Ships
Harmless medicines mint-furosemide	$321.2K	7
Mint celecoxib CAPS 200MG 100's	$286.0K	8
Pharmaceutical drugs and medicine.mint	$266.5K	8
Amlodipine	$223.0K	11
Itraconazole capsules 100MG batch no.	$200.0K	4
Mint-eplerenone 25MG tablets 90	$200.0K	4
Mint celecoxib CAPS 100MG 100's	$187.4K	8
Nadolol tablets USP 40MG (100`s)	$153.6K	5
Eplerenone 25MG tablets 90	$150.0K	3
Spironolactone tablets USP 25MG (500s-count)	$133.4K	4
Mint-dutasteride - dutasteride	$132.1K	4
Simvastatin tablet	$120.6K	5
Citalopram tablets USP 20MG batch no.	$113.7K	4
Pharmaceutical drugs and medicine mint	$110.0K	4
Nadolol tablets USP 40MG ( 100`s count).	$110.0K	4

Mint Pharmaceuticals Inc imports 292 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Spironolactone	Diuretics	$1.4M	27	0.7%	13
2	Furosemide	Diuretics	$750.0K	15	1.1%	18
3	Itraconazole	Antifungals	$250.0K	5	0.9%	17
4	Indomethacin	Analgesics & Antipyretics	$132.4K	6	1.4%	6

Mint Pharmaceuticals Inc imports 4 pharmaceutical products across 3 categories into Canada totaling $2.5M.

Mint Pharmaceuticals Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Mint Pharmaceuticals Inc. is a Canadian-owned generic pharmaceutical company headquartered in Mississauga, Ontario, near Toronto Pearson International Airport. Established in 2007, Mint Pharmaceuticals specializes in delivering high-quality and affordable generic pharmaceuticals and healthcare solutions to the Canadian market. The company offers a robust portfolio of over 100 molecules and several hundred products, maintaining an industry-leading 99% fill rate. Over the past decade, Mint has successfully averted more than 20 national drug shortages, demonstrating its best-in-class supply chain capabilities and differentiated product offerings.

In September 2025, Mint Pharmaceuticals announced a strategic partnership with Bayer Canada to distribute ADALAT® XL® 30 mg tablets in Canada, reinforcing its commitment to providing essential medications to Canadian patients. The company's mission is to improve healthcare for all Canadians by being the leading supplier of high-quality and affordable generic pharmaceuticals, focusing on consistent supply, innovation, and exceptional customer service.

2Distribution Network

Mint Pharmaceuticals operates a robust distribution network across Canada, with its headquarters strategically located near Toronto Pearson International Airport in Mississauga, Ontario. This location facilitates efficient logistics and timely delivery of pharmaceutical products nationwide. The company's supply chain capabilities have been instrumental in averting over 20 national drug shortages in the past decade, underscoring its commitment to maintaining a reliable supply of essential medications.

3Industry Role

Mint Pharmaceuticals Inc. functions as a primary wholesaler and distributor within Canada's pharmaceutical supply chain. By importing generic pharmaceutical formulations from various international suppliers, including Indian manufacturers, Mint ensures a consistent and affordable supply of medications to the Canadian market. The company's strategic partnerships, such as the one with Bayer Canada to distribute ADALAT® XL® 30 mg tablets, further solidify its role in the pharmaceutical distribution landscape.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Mint Pharmaceuticals Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Mint Pharmaceuticals Inc. imports a diverse range of generic pharmaceutical formulations from India, encompassing 292 unique formulations across various therapeutic categories. The company's top five imported products—spironolactone, furosemide, itraconazole, indomethacin, and others—account for 100% of its import value, indicating a high level of portfolio concentration. This concentration suggests a strategic focus on specific therapeutic areas, potentially leveraging established supplier relationships and market demand. However, the absence of a single dominant supplier indicates a diversified sourcing strategy, which may mitigate risks associated with over-reliance on a single source.

2Supply Chain Resilience

Mint Pharmaceuticals Inc. demonstrates resilience in its Indian supply chain through diversified sourcing from 20 unique suppliers. This approach reduces dependency on any single supplier, enhancing the company's ability to navigate potential disruptions. The importation of 292 unique formulations indicates a broad product base, which can buffer against market fluctuations and supply chain challenges. While specific details about backup suppliers and shipping routes are not publicly disclosed, Mint's strategic partnerships and robust supply chain capabilities suggest a proactive approach to ensuring continuity and compliance with regulatory standards.

Importing Pharmaceuticals into Canada — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Canada

1Regulatory Authority & Framework

In Canada, the importation and distribution of pharmaceutical products are regulated by Health Canada under the Food and Drugs Act and its associated Regulations. This framework ensures that all drugs, including prescription and non-prescription medications, biologics, and radiopharmaceuticals, meet rigorous standards for safety, effectiveness, and quality. Health Canada's oversight encompasses the entire lifecycle of pharmaceutical products, from importation to post-market surveillance, to safeguard public health. (canada.ca)

2Import Licensing & GMP

To import pharmaceutical products into Canada, companies must obtain an Establishment Licence (EL) for the activity of importation. Additionally, each drug product must have a Drug Identification Number (DIN) assigned by Health Canada prior to being marketed. The foreign manufacturing site must be listed on the importer's EL, and the manufacturing facility must comply with Good Manufacturing Practices (GMP) recognized by Health Canada. These requirements ensure that imported pharmaceutical products meet Canadian standards for quality and safety. (canada.ca)

3Quality & Labeling

Mint Pharmaceuticals Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Mint Pharmaceuticals Inc.'s focus on importing generic formulations in therapeutic categories such as diuretics, antifungals, and analgesics & antipyretics aligns with market demand for affordable and effective treatments in these areas. The company's top five imported products—spironolactone, furosemide, itraconazole, indomethacin, and others—account for 100% of its import value, indicating a strategic emphasis on these therapeutic classes. This concentration suggests that Mint is addressing prevalent health conditions in Canada, thereby meeting significant patient needs.

2Sourcing Profile

Mint Pharmaceuticals Inc. employs a diversified sourcing strategy by importing generic drug formulations from 20 unique suppliers in India. This approach reduces dependency on any single supplier and enhances the company's ability to navigate potential disruptions in the supply chain. The importation of 292 unique formulations indicates a broad product base, which can buffer against market fluctuations and supply chain challenges. While specific details about backup suppliers and shipping routes are not publicly disclosed, Mint's strategic partnerships and robust supply chain capabilities suggest a proactive approach to ensuring continuity and compliance with regulatory standards.

3Market Positioning

Seller's Guide — How to Become a Supplier to Mint Pharmaceuticals Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Mint Pharmaceuticals Inc., given the company's diversified sourcing strategy and focus on specific therapeutic areas. Indian exporters can explore partnerships with Mint by offering generic formulations that align with the company's product portfolio, particularly in diuretics, antifungals, and analgesics & antipyretics. Establishing such partnerships could facilitate entry into the Canadian market and contribute to meeting the demand for affordable and effective pharmaceutical products.

2Requirements & Qualifications

Indian exporters seeking to supply Mint Pharmaceuticals Inc. and the Canadian market must ensure that their manufacturing facilities comply with Good Manufacturing Practices (GMP) recognized by Health Canada. Each drug product must have a Drug Identification Number (DIN) assigned by Health Canada prior to being marketed. Additionally, the foreign manufacturing site must be listed on the importer's Establishment Licence (EL) for the activity of importation. These requirements ensure that imported pharmaceutical products meet Canadian standards for quality and safety. (canada.ca)

How to Approach

Frequently Asked Questions — Mint Pharmaceuticals Inc

What products does Mint Pharmaceuticals Inc import from India?

Mint Pharmaceuticals Inc imports 4 pharmaceutical products across 3 categories. Top imports: Spironolactone ($1.4M), Furosemide ($750.0K), Itraconazole ($250.0K), Indomethacin ($132.4K).

Who supplies pharmaceuticals to Mint Pharmaceuticals Inc from India?

Mint Pharmaceuticals Inc sources from 20 verified Indian suppliers. The primary supplier is Cohance Lifesciences Limited (14.4% of imports, $1.7M).

What is Mint Pharmaceuticals Inc's total pharmaceutical import value?

Mint Pharmaceuticals Inc's total pharmaceutical import value from India is $2.5M, based on 53 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Mint Pharmaceuticals Inc focus on?

Mint Pharmaceuticals Inc imports across 3 categories. The largest: Diuretics (84.6%), Antifungals (10.1%), Analgesics & Antipyretics (5.3%).

Get Full Mint Pharmaceuticals Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.